63 related articles for article (PubMed ID: 16315243)
1. Target ability and therapy efficacy of immunoliposomes using a humanized antihepatoma disulfide-stabilized Fv fragment on tumor cells.
Hu H; Chen D; Liu Y; Deng Y; Yang S; Qiao M; Zhao J; Zhao X
J Pharm Sci; 2006 Jan; 95(1):192-9. PubMed ID: 16315243
[TBL] [Abstract][Full Text] [Related]
2. [Preparation and in vitro tumor cells selectivity of sterically stabilized immunoliposomal peptides in bee venom].
Hu HY; Chen DW; Liu YF; Qiao MX; Zhao XL
Yao Xue Xue Bao; 2007 Nov; 42(11):1201-5. PubMed ID: 18300479
[TBL] [Abstract][Full Text] [Related]
3. Preparation and targeted delivery of immunoliposomes bearing poly(ethylene glycol)-coupled humanized anti-hepatoma disulfide-stabilized Fv (hdsFv25) in vitro.
Hu H; Chen D; Liu Y; Deng Y; Yang S; Qiao M; Zhao J; Zhao X
Pharmazie; 2006 Aug; 61(8):685-8. PubMed ID: 16964711
[TBL] [Abstract][Full Text] [Related]
4. Effect of polypeptides in bee venom on growth inhibition and apoptosis induction of the human hepatoma cell line SMMC-7721 in-vitro and Balb/c nude mice in-vivo.
Hu H; Chen D; Li Y; Zhang X
J Pharm Pharmacol; 2006 Jan; 58(1):83-9. PubMed ID: 16393467
[TBL] [Abstract][Full Text] [Related]
5. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
6. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
Désormeaux A; Bergeron MG
Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system.
Hussain S; Plückthun A; Allen TM; Zangemeister-Wittke U
Mol Cancer Ther; 2007 Nov; 6(11):3019-27. PubMed ID: 18025286
[TBL] [Abstract][Full Text] [Related]
8. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
9. The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002.
Siwak DR; Tari AM; Lopez-Berestein G
Clin Cancer Res; 2002 Apr; 8(4):955-6. PubMed ID: 11948099
[No Abstract] [Full Text] [Related]
10. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.
Nielsen UB; Kirpotin DB; Pickering EM; Hong K; Park JW; Refaat Shalaby M; Shao Y; Benz CC; Marks JD
Biochim Biophys Acta; 2002 Aug; 1591(1-3):109-118. PubMed ID: 12183061
[TBL] [Abstract][Full Text] [Related]
13. Anti-hepatoma human single-chain Fv antibody and adriamycin conjugates with potent antitumor activity.
Chen L; Liu YH; Li YH; Jiang Y; Xie PL; Zhou GH; Li GC
Int Immunopharmacol; 2014 Jan; 18(1):20-6. PubMed ID: 24239629
[TBL] [Abstract][Full Text] [Related]
14. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.
Nam SM; Kim HS; Ahn WS; Park YS
Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027
[TBL] [Abstract][Full Text] [Related]
15. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
17. Liposomes modified with YIGSR peptide for tumor targeting.
Dubey PK; Singodia D; Vyas SP
J Drug Target; 2010 Jun; 18(5):373-80. PubMed ID: 20020817
[TBL] [Abstract][Full Text] [Related]
18. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
[TBL] [Abstract][Full Text] [Related]
19. Development of anti-HB-EGF immunoliposomes for the treatment of breast cancer.
Nishikawa K; Asai T; Shigematsu H; Shimizu K; Kato H; Asano Y; Takashima S; Mekada E; Oku N; Minamino T
J Control Release; 2012 Jun; 160(2):274-80. PubMed ID: 22020380
[TBL] [Abstract][Full Text] [Related]
20. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.
Yang C; Liu HZ; Lu WD; Fu ZX
Oncol Rep; 2011 Jun; 25(6):1621-8. PubMed ID: 21455585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
